Search Results - Weiguo Su

  • Showing 1 - 10 results of 10
Refine Results
  1. 1

    Significantly improving mechanical properties of CF/PAI composites: the influence of interfacial modification coupled with post heat treatment by Fang Zhou, Zhenbo Zhao, Deqi Jing, Xinghua Zhang, Peng Wang, Weiguo Su, Shouchun Zhang

    Get full text
    Article


  2. 2

    Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies by Shuwen Jiang, Xiangkun Li, Weifang Xue, Sumei Xia, Jian Wang, Yang Sai, Guangxiu Dai, Weiguo Su

    Published in Frontiers in Pharmacology (2024-06-01)
    Get full text
    Article


  3. 3

    Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study by Rui-Hua Xu, Jin Li, Yuxian Bai, Jianming Xu, Tianshu Liu, Lin Shen, Liwei Wang, Hongming Pan, Junning Cao, Dongsheng Zhang, Songhua Fan, Ye Hua, Weiguo Su

    Published in Journal of Hematology & Oncology (2017-01-01)
    Get full text
    Article


  4. 4

    Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung can... by Ying Cheng, Panpan Zhang, Ming Lu, Zhendong Chen, Lijie Song, Si Shi, Feng Ye, Xing Zhang, Baorui Liu, Dongmei Ji, Yanqiao Zhang, Weiguo Su, Michael Shi, Songhua Fan, Panfeng Tan, Chen Zhong

    Published in Cancer Immunology, Immunotherapy (2025-02-01)
    Get full text
    Article


  5. 5

    Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study by Yi Wang, Yifu He, Zhiqiang Wang, Haijun Zhong, Zuoxing Niu, Shujun Yang, Tao Zhang, Liangjun Zhu, Yongqian Shu, Jianjun Peng, Yan Song, Jian Li, Ying Yuan, Haibo Zhang, Gengsheng Yu, Yunqi Hua, Jianjun Xiao, Jianfei Fu, Yulong Zheng, Jingyu Zhu, Hua Xue, Xian Luo, Michael Shi, Weiguo Su, Jin Li, Shukui Qin

    Published in Therapeutic Advances in Medical Oncology (2025-08-01)
    Get full text
    Article


  6. 6

    Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 studyResearch in contex... by Junning Cao, Guangliang Chen, Lihua Qiu, Liling Zhang, Ming Jiang, Ying Cheng, Qiaohua Zhang, Lihong Liu, Ping Li, Yuerong Shuang, Huaqing Wang, Hongwei Xue, Huijing Wu, Meifang Zheng, Keshu Zhou, Zhiming Li, Hongmei Jing, Wei Yang, Zunmin Zhu, Wenyu Li, Jiaxuan Wangwu, Heyu Huang, Qiantao Jia, Dongmei Chen, Songhua Fan, M. Ming Shi, Weiguo Su

    Published in EClinicalMedicine (2025-09-01)
    Get full text
    Article


  7. 7

    Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors by Yuqin Song, Junning Cao, Qingyuan Zhang, Caixia Li, Lugui Qiu, Junyuan Qi, Huilai Zhang, Wenyu Li, Lihong Liu, Hongmei Jing, Keshu Zhou, Weijing Zhang, Liling Zhang, Daqi Li, Liqun Zou, Haiyan Yang, Wenbin Qian, Hui Zhou, Jianda Hu, Hongyan Yin, Sisi Fu, Songhua Fan, Qian Xu, Jian Wang, Xiaoyun Jia, Guangxiu Dai, Weiguo Su, Jun Zhu

    Published in Haematologica (2024-01-01)
    Get full text
    Article


  8. 8

    Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring exon 14 skipping alterations: a analysis of a pivotal phase 2 study by Yongfeng Yu, Yongxin Ren, Jian Fang, Lejie Cao, Zongan Liang, Qisen Guo, Sen Han, Zimei Ji, Ye Wang, Yulan Sun, Yuan Chen, Xingya Li, Hua Xu, Jianying Zhou, Liyan Jiang, Ying Cheng, Zhigang Han, Jianhua Shi, Gongyan Chen, Rui Ma, Yun Fan, Sanyuan Sun, Longxian Jiao, Xiaoyun Jia, Linfang Wang, Puhan Lu, Qian Xu, Xian Luo, Weiguo Su, Shun Lu

    Published in Therapeutic Advances in Medical Oncology (2022-10-01)
    Get full text
    Article


  9. 9

    P539: A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING I... by Lijuan Hu, Wei-LI Zhao, Wen Wu, Xudong Wei, Ruihua MI, Yu Hu, Qiubai LI, Wenjuan He, Juan LI, Yugang Dong, Hehua Wang, Xuhan Zhang, Yu Zhang, Zhongyuan Xu, Hui Liu, Zhen Cai, Jie Sun, Yajing Xu, Zhiping Jiang, Cheng Zhang, Guo Chen, Tiejun Gong, Qinghua Tang, Hongmei Jing, Lan MA, Sujun Gao, Qiqi Liu, Zeyu Zhong, Yongxin Ren, Jian Chen, Songhua Fan, Michael Shi, Weiguo Su, Xiaojun Huang

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  10. 10

    Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations by Shun Lu, MD, Jian Fang, MD, Xingya Li, MD, Lejie Cao, MD, Jianying Zhou, MD, Qisen Guo, MD, Zongan Liang, MD, Ying Cheng, MD, Liyan Jiang, MD, Nong Yang, MD, Zhigang Han, MD, Jianhua Shi, MD, Yuan Chen, MD, Hua Xu, MD, Helong Zhang, MD, Gongyan Chen, MD, Rui Ma, MD, Sanyuan Sun, MD, Yun Fan, MD, Songhua Fan, MD, Jie Yu, MD, Puhan Lu, PhD, Xian Luo, MS, Weiguo Su, PhD

    Published in JTO Clinical and Research Reports (2022-10-01)
    Get full text
    Article


Search Tools: